![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Non-inferiority of dual-therapy with darunavir/ritonavir plus 3TC vs. triple therapy with darunavir/ritonavir plus TDF/FTC or ABC/3TC for maintenance of viral suppression: 48-week results of the DUAL-GESIDA 8014-RIS-EST45 Trial - DUAL: "DarUnavir And Lamivudine"
|
|
|
Reported by Jules Levin
HIV Glasgow 2016 Oct 23-26
Federico Pulido. Esteban Ribera. Maria Lagarde. Ignacio Perez-Valero. Jesús Santos. Jose A. Iribarren. Antonio Payeras. Pere Domingo. Jose Sanz. Miguel Cervero. Adrian Curran. Francisco J. Rodriguez. Maria J. Tellez . Pablo Ryan. Pilar Barrufet. Hernando Knobel. Antonio Rivero.
Belen Alejos. Maria Yllescas. Jose R. Arribas.
DUAL-GESIDA-8014-RIS-EST45 Study Group
![HIV1](../images/111016/110916-9/HIV1.gif)
![HIV2](../images/111016/110916-9/HIV2.gif)
![HIV3](../images/111016/110916-9/HIV3.gif)
![HIV4](../images/111016/110916-9/HIV4.gif)
![HIV5](../images/111016/110916-9/HIV5.gif)
![HIV6](../images/111016/110916-9/HIV6.gif)
![HIV7](../images/111016/110916-9/HIV7.gif)
![HIV8](../images/111016/110916-9/HIV8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|